NCT06187402 · LaNova Medicines Limited
A Study of LM-24C5 For Advanced Solid Tumors
What this study is about
To assess the safety and how well patients handle the treatment, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.
View original scientific description
To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.
Interventions
DRUG
LM-24C5
Administered intravenously
Primary outcome measures
Incidence of adverse events (AEs)
Time frame: 60 weeks
Phase 1
Incidence of dose-limiting toxicity (DLT)
Time frame: 60 weeks
Phase 1
Incidence of serious adverse event (SAE)
Time frame: 60 weeks
Phase 1
Ear Temperature
Time frame: 60 weeks
Phase 1
Pulse in BPM(Beat per Minute)
Time frame: 60 weeks
Phase 1
Blood Pressure in mmHg (Both Systolic and Diastolic blood pressure)
Time frame: 60 weeks
Phase 1
Number of participants with abnormal Hematology test results
Time frame: 60 weeks
Phase 1
Number of participants with abnormal Urinalysis test results
Time frame: 60 weeks
Phase 1
Number of participants with abnormal Blood Biochemistry test results
Time frame: 60 weeks
Phase 1
Number of participants with abnormal Coagulation test results in PT(Prothrombin time), APTT(Activated partial thromboplastin time), FIB(Fibrinogen), TT(Thrombin time) and INR(International normalized ratio).
Time frame: 60 weeks
Phase 1
Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage
Time frame: 60 weeks
Phase 1
12-lead electrocardiogram (ECG) in RR, PR, QRS, QT, QTcF etc.
Time frame: 60 weeks
Phase 1
ECOG(Eastern Cooperative Oncology Group) score
Time frame: 60 weeks
Phase 1
Overall Response Rate (ORR)
Time frame: 36 weeks
Phase 2
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Subjects who are fully informed of the purpose, nature, method and possible adverse reactions of the study, and are willing to participate in the study and sign the informed consent form (ICF) prior to any study related procedures. 2. Aged ≥18 years old when sign the ICF, male or female. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and no deterioration within 2 weeks prior to the first dose. 4. Life expectancy ≥ 3 months. 5. Subjects must have histological or cytological confirmation of recurrent or refractory advanced solid tumors, and have progressed on standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy. 6. Formalin-fixed paraffin-embedded (FFPE) tumor tissue samples meet the minimum requirements. 7. At least one measurable lesion according to RECIST v1.1. 8. Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first
Where
- Los Angeles, California
- Ocala, Florida
- Indianapolis, Indiana
- Cincinnati, Ohio
- Dallas, Texas
- Fairfax, Virginia
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Sep 9, 2025 · Source of record for eligibility and locations